DE60016039D1 - Verfahren und verbindungen für die hemmung von mrp1 - Google Patents

Verfahren und verbindungen für die hemmung von mrp1

Info

Publication number
DE60016039D1
DE60016039D1 DE60016039T DE60016039T DE60016039D1 DE 60016039 D1 DE60016039 D1 DE 60016039D1 DE 60016039 T DE60016039 T DE 60016039T DE 60016039 T DE60016039 T DE 60016039T DE 60016039 D1 DE60016039 D1 DE 60016039D1
Authority
DE
Germany
Prior art keywords
mrp1
inhibition
compounds
mammal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60016039T
Other languages
English (en)
Other versions
DE60016039T2 (de
Inventor
Rosanne Bonjouklian
Daniel Cohen
Michael Gruber
Webb Johnson
Nickolaus Jungheim
Stanley Kroin
Ambrose Lander
Ho-Shen Lin
Christopher Lohman
Stephen Muehl
Hurst Norman
Francis Patel
Enrico Richett
Jeff Thrasher
Sreenivasarao Vepachedu
Todd White
Yongping Xie
Jeremy Schulenburg York
Lee Parkhurst
Quiping Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60016039D1 publication Critical patent/DE60016039D1/de
Application granted granted Critical
Publication of DE60016039T2 publication Critical patent/DE60016039T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60016039T 1999-12-22 2000-12-11 Verfahren und verbindungen für die hemmung von mrp1 Expired - Fee Related DE60016039T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17137399P 1999-12-22 1999-12-22
US171373P 1999-12-22
US22607600P 2000-08-17 2000-08-17
US226076P 2000-08-17
US23453900P 2000-09-22 2000-09-22
US234539P 2000-09-22
PCT/US2000/032443 WO2001046199A1 (en) 1999-12-22 2000-12-11 Methods and compounds for inhibiting mrp1

Publications (2)

Publication Number Publication Date
DE60016039D1 true DE60016039D1 (de) 2004-12-23
DE60016039T2 DE60016039T2 (de) 2005-08-11

Family

ID=27389968

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016039T Expired - Fee Related DE60016039T2 (de) 1999-12-22 2000-12-11 Verfahren und verbindungen für die hemmung von mrp1

Country Status (12)

Country Link
EP (1) EP1250340B1 (de)
JP (1) JP2003518125A (de)
AT (1) ATE282623T1 (de)
AU (1) AU2251901A (de)
CA (1) CA2395513A1 (de)
CO (1) CO5261493A1 (de)
DE (1) DE60016039T2 (de)
ES (1) ES2233487T3 (de)
PE (1) PE20011085A1 (de)
PT (1) PT1250340E (de)
SV (1) SV2002000244A (de)
WO (1) WO2001046199A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301518A1 (de) * 2000-06-14 2003-04-16 Eli Lilly And Company Tricyclische verbindungen mit mrp1-inhibierender wirkung
EP1296953A2 (de) 2000-06-23 2003-04-02 Eli Lilly And Company Methoden und verbindungen zur inhibierung von mrp1
US20050004122A1 (en) * 2002-08-14 2005-01-06 Brown Bradley B. Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US20060035920A1 (en) * 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
KR20070073887A (ko) * 2004-10-12 2007-07-10 그렌마크 파머수티칼스 에스. 아. 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정
JP4845372B2 (ja) * 2004-11-30 2011-12-28 広栄化学工業株式会社 光学活性２−ヒドロキシエステル化合物の製造方法
KR20100108348A (ko) 2007-11-23 2010-10-06 레오 파마 에이/에스 질병 치료용의 신규한 사이클릭 탄화수소 화합물
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2012000498A1 (en) * 2010-06-30 2012-01-05 Leo Pharma A/S New polymorphic form of a calcimimetic compound
RU2599788C2 (ru) * 2010-06-30 2016-10-20 Лео Фарма А/С Новая полиморфная форма кальцимиметического соединения
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN104230744B (zh) * 2014-09-01 2016-06-08 湖南尔康制药股份有限公司 一种替加环素原料药的生产方法
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EP3215141A4 (de) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Immunregulatorische wirkstoffe
CN112409207B (zh) * 2019-08-22 2022-11-22 新发药业有限公司 一种醚菌胺的制备方法
CN114890940A (zh) * 2022-04-21 2022-08-12 嘉兴瑞驰生物科技有限公司 一种6-甲氧基-2-吡啶甲酸的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980608A (en) * 1998-01-07 1999-11-09 Advanced Technology Materials, Inc. Throughflow gas storage and dispensing system
BR9909446A (pt) * 1998-04-08 2000-12-12 Lilly Co Eli Métodos para inibição de mrp1
PL343313A1 (en) * 1998-04-08 2001-08-13 Lilly Co Eli Methods for inhibiting mrp1
HUP0101736A3 (en) * 1998-04-08 2002-04-29 Lilly Co Eli Isoxazolo[3,4-c]quinoline derivatives, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2395513A1 (en) 2001-06-28
ATE282623T1 (de) 2004-12-15
CO5261493A1 (es) 2003-03-31
PE20011085A1 (es) 2001-10-24
PT1250340E (pt) 2005-04-29
AU2251901A (en) 2001-07-03
EP1250340A1 (de) 2002-10-23
ES2233487T3 (es) 2005-06-16
WO2001046199A1 (en) 2001-06-28
SV2002000244A (es) 2002-07-16
JP2003518125A (ja) 2003-06-03
DE60016039T2 (de) 2005-08-11
EP1250340B1 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
DE60016039D1 (de) Verfahren und verbindungen für die hemmung von mrp1
NO990855D0 (no) Substituerte sykliske amin-metallprotease-inhibitorer
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE69711391D1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
NO20003018D0 (no) Triazinangiogenese-inhibitorer
BG103415A (en) Heteroaryl succinamides and their application as inhibitors of metalloproteinase
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
DE60013575D1 (de) Zelladhäsion inhibierende entzündungshemmende und immunsuppressive verbindungen
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2004033423A3 (en) Anticancer compounds
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
EA200100930A1 (ru) Способ лечения хозл
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
IL95727A0 (en) Substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
DK1353660T3 (da) Anvendelse af substituerede 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens
PT1276722E (pt) Inibidores de naftamidina-uroquinase
ATE488489T1 (de) Verfahren zur reduktiven deshalogenierung
ATE284867T1 (de) Verfahren zur herstellung chiraler verbindungen
ATE330612T1 (de) Verfahren zur herstellung von benazeprilhydrochloride
DE60003711D1 (de) Verfahren zur herstellung von peptidzwischenprodukten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee